Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00153881 · ClinicalTrials.gov registry record · Phase 1
Docetaxel and Carboplatin Followed by Oral Capecitabine, Docetaxel and Radiation for Esophageal Cancer
A Phase 1 study of Esophageal Neoplasms, sponsored by Dartmouth-Hitchcock Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
- 1
- Study location
NCT00153881: Completed Phase 1 study of Esophageal Neoplasms, sponsored by Dartmouth-Hitchcock Medical Center.
NCT00153881 is a Phase 1 study of Esophageal Neoplasms that has completed, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 44 participants, below the 1,485-participant average among 12 other Esophageal Neoplasms trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00153881, a Phase 1 study of Esophageal Neoplasms, has completed, sponsored by Dartmouth-Hitchcock Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective is to determine the maximum tolerated dose of oral capecitabine, in combination with fixed doses of weekly docetaxel, and concurrent thoracic radiation for the treatment of patients with clinical stage II-III cancer of the esophagus and gastroesophageal junction.
Conditions Studied
Interventions
- DRUG Capecitabine (Xeloda)
Study Locations (1)
New Hampshire
- Norris Cotton Cancer Center - Lebanon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2000-02 |
| Est. Completion | 2013-09 |
| Phase | Phase 1 |
What the finished NCT00153881 record still lists
NCT00153881 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 1,485-participant average among 12 other Esophageal Neoplasms trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Esophageal Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which Capecitabine (Xeloda) is the first listed.
NCT00153881 reports a single indexed study location in New Hampshire.
Frequently Asked Questions
What is clinical trial NCT00153881 about?
NCT00153881 is a clinical study titled "Docetaxel and Carboplatin Followed by Oral Capecitabine, Docetaxel and Radiation for Esophageal Cancer". The primary objective is to determine the maximum tolerated dose of oral capecitabine, in combination with fixed doses of weekly docetaxel, and concurrent thoracic radiation for the treatment of patients with clinical stage II-III cancer of the esophagus and gastroesophageal junction.
What is the current status of trial NCT00153881?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2000-02. Estimated completion is 2013-09.
What conditions does trial NCT00153881 study?
This clinical trial studies the following conditions: Esophageal Neoplasms.
What interventions are being tested in trial NCT00153881?
The interventions under investigation include: Capecitabine (Xeloda) (DRUG).
Who is sponsoring clinical trial NCT00153881?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00153881 being conducted?
This trial has 1 study location across New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophageal Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00153881's enrollment target sits among peer trials
44 13th of 12 the lowest of 12 other Esophageal Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Esophageal Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
RECRUITING · Phase 1
-
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
RECRUITING · Phase 1
-
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
RECRUITING · Phase 1
-
A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab
COMPLETED · Phase 1
-
Metachronic Brain Metastases After Esophagectomy for Esophageal Cancer (METABREC)
RECRUITING
-
Mayo Clinic Upper Digestive Disease Survey
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia